



The Medical Oncology Association of Southern California (MOASC) opposes the Trump Administration’s Executive Order known as “Lowering Drug Prices by Putting Americans First”. This policy would implement a “Most Favored Nation” model, which would base certain Medicare Part B and Part D drugs and biologics at no more than the lowest price offered in foreign countries. This policy threatens to significantly reduce development of oncologist-administered cancer medicines and limit access to prescription cancer drugs during a global pandemic.

Medicines covered under Medicare Part B and Part D treat our nation’s sickest and most vulnerable seniors – many of them cancer patients. American patients have access to a large variety of cancer treatments that are not available in the countries this EO would base prices from. Survival rates from cancer are higher in the U.S. compared to any other country and patients will undeniably suffer from a loss of access to these life-saving treatment options should we import these foreign price controls.

Now is not the time for an Executive Order that negatively impacts cancer patients, particularly during an unprecedented pandemic, when access to quality cancer care and screenings is already limited. MOASC urges the administration to reject the “Most Favored Nation” policy and to keep looking for workable solutions that benefit patients first.

Warren H. Fong, M.D., F.A.C.P.
President
Medical Oncology Association of Southern California, Inc.
www.moasc.org